IMMUNEERING CORP - CLASS A
IMRX · NASDAQ
Updated at 2026-10-14 09:06:44
- Today's High
- $3.86
- Today’s Low
- $3.54
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $3.94
- Previous Close
- $3.86
- Volume
- 529.79K
- Market Cap
- $249.73M
- P/E Ratio
- --
- EPS
- $-1.03
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 245 MAIN STREET, CAMBRIDGE, MA, UNITED STATES, 02142
- Country
- US
- Listing Date
- 2021-07-30
- Fiscal Year End
- December
- Shares Outstanding
- 64.7M
- CIK
- 0001790340
- Website
- immuneering.com
Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its proprietary drug discovery platforms. Leveraging sophisticated bioinformatics and machine learning, the company focuses on identifying and refining drug candidates that selectively intervene in pivotal biological pathways, thereby enhancing efficacy and reducing toxicity. With a robust pipeline of novel therapies and strategic alliances, Immuneering is well-positioned to thrive in the rapidly evolving domains of personalized medicine and targeted oncology, offering significant investment opportunities for institutional investors.
Financial Metrics
Revenue
2026-06-30
$360.95K
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$19M
2026-03-31
$15.15M
2025-12-31
$13.14M
2025-09-30
$15.38M
Net Income
2026-06-30
-$17.27M
2026-03-31
-$13.46M
2025-12-31
-$11.58M
2025-09-30
-$14.96M
Net Profit Margin
2026-06-30
-4.78K%
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.27
2026-03-31
$-0.21
2025-12-31
$-0.18
2025-09-30
$-0.38
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$17.17M
2026-03-31
-$15.24M
2025-12-31
-$14.08M
2025-09-30
-$15.29M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $360.95K | $0 | $0 | $0 |
| Operating Expenses | $19M | $15.15M | $13.14M | $15.38M |
| Net Income | -$17.27M | -$13.46M | -$11.58M | -$14.96M |
| Net Profit Margin | -4.78K% | -- | -- | -- |
| Earnings Per Share | $-0.27 | $-0.21 | $-0.18 | $-0.38 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$17.17M | -$15.24M | -$14.08M | -$15.29M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.